<SEC-DOCUMENT>0000904454-24-000393.txt : 20240620
<SEC-HEADER>0000904454-24-000393.hdr.sgml : 20240620
<ACCEPTANCE-DATETIME>20240620203537
ACCESSION NUMBER:		0000904454-24-000393
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240620
DATE AS OF CHANGE:		20240620

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASSEMBLY BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001426800
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-85836
		FILM NUMBER:		241058166

	BUSINESS ADDRESS:	
		STREET 1:		TWO TOWER PLACE
		STREET 2:		7TH FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(833) 409-4583

	MAIL ADDRESS:	
		STREET 1:		TWO TOWER PLACE
		STREET 2:		7TH FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VENTRUS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20080211

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>s13da_061724-assemblybio.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 13D<BR>
Under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Amendment No. 1)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><B>ASSEMBLY BIOSCIENCES, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center">(Name of Issuer)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><B>Common Stock, par value $0.001</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center">(Title of Class of Securities)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><B>0453961080</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center">(CUSIP Number)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Gilead Sciences, Inc.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>333 Lakeside Drive</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Foster City, California 94404</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><B>650-574-3000</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center">(Name, Address and Telephone Number of Person<BR>
Authorized to Receive Notices and Communications)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><B>June 17, 2024</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: center">(Date of Event Which Requires Filing of this Statement)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the filing person has previously filed a statement
on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of &sect; 240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box [ ].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Note: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See &sect; 240.13d-7(b) for other parties to whom copies are
to be sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">*The remainder of this cover page shall be filled out
for a reporting person&rsquo;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The information required on the remainder of this cover
page shall not be deemed to be &ldquo;filed&rdquo; for the purpose of Section 18 of the Securities Exchange Act of 1934 (&ldquo;<U>Act</U>&rdquo;)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.9pt; font: 10pt Times New Roman, Times, Serif">CUSIP No. 0453961080</TD>
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.65pt; font: 10pt Times New Roman, Times, Serif; text-align: right">Page 2</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>1</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">NAME OF REPORTING PERSONS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">Gilead Sciences, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>2</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-left: 5.65pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0 17.3pt; text-align: justify">(a) [ ]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 6pt 17.3pt; text-align: justify">(b) [ ]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>3</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">SEC USE ONLY</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 5.9pt; padding-left: 5.65pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>4</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">SOURCE OF FUNDS (See Instructions)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">WC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>5</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 12pt">[ ]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>6</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">CITIZENSHIP OR PLACE OF ORGANIZATION</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">Delaware</FONT></TD></TR>
  <TR>
    <TD ROWSPAN="8" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center"><FONT STYLE="font-size: 9pt">NUMBER OF<BR>
SHARES<BR>
BENEFICIALLY<BR>
OWNED BY<BR>
EACH<BR>
REPORTING<BR>
PERSON<BR>
WITH</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>7</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">SOLE VOTING POWER</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">1,268,972</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>8</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">SHARED VOTING POWER</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">0</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>9</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">SOLE DISPOSITIVE POWER</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">1,268,972</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>10</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">SHARED DISPOSITIVE POWER</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">0</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>11</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">1,268,972</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>12</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">[ ]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>13</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">19.99% (1)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.9pt; text-align: justify"><FONT STYLE="font-size: 12pt"><B>14</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.9pt; padding-left: 5.65pt"><FONT STYLE="font-size: 9pt">TYPE OF REPORTING PERSON (See Instructions)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 11pt">CO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(1)</TD>
    <TD>Based upon 6,345,561 shares of common stock of the Issuer issued and outstanding, which 6,345,561 shares is equal to the sum of (i) 5,531,561 shares of common stock of the Issuer issued and outstanding as of June 14, 2024, as represented by the Issuer to Gilead Sciences, Inc. in the Securities Purchase Agreement, dated June 17, 2024, between the Issuer and Gilead Sciences, Inc., plus (ii) 179,500 shares of common stock issued by the Issuer to Gilead Sciences, Inc. on June 17, 2024 pursuant to the Securities Purchase Agreement, dated June 17, 2024, between the Issuer and Gilead Sciences, Inc., plus (iii) 634,500 shares of common stock issued by the Issuer to Armistice Capital LLC on June 17, 2024 pursuant to the Securities Purchase Agreement, dated June 16, 2024, between the Issuer and Armistice Capital LLC.</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.9pt">CUSIP No. 0453961080</TD>
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.65pt; text-align: right">Page 3</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Introduction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Amendment No. 1 (&ldquo;<U>Amendment No. 1</U>&rdquo;)
amends and supplements the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;)
on October 25, 2023 (the &ldquo;<U>Schedule 13D</U>&rdquo;), which relates to the common stock, par value $0.001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;), of Assembly Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Issuer</U>&rdquo;). <FONT STYLE="background-color: white">Unless
otherwise indicated, all capitalized terms used herein shall have the meanings set forth in the Schedule 13D and, unless amended hereby,
all information previously filed remains in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><B>Item 3.</B><FONT STYLE="font-size: 3pt">&nbsp;</FONT>
<B>Source and Amount of Funds or Other Consideration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Item 3 is amended to add the following paragraph immediately
following the first paragraph:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On June 17, 2024, Gilead entered into a Securities
Purchase Agreement, between the Issuer and Gilead Sciences, Inc. (the &ldquo;<U>2024 Purchase Agreement</U>&rdquo;), pursuant to which
Gilead purchased 179,500 shares of Common Stock and a warrant to purchase 179,500 shares of Common Stock (the &ldquo;<U>Warrant</U>&rdquo;)
at a combined purchase price of $15.46 per share of Common Stock and accompanying Warrant, which purchase occurred on June 17, 2024. The
total consideration for such purchase was approximately $2.8 million, and such consideration was obtained from the available cash resources
of Gilead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><B>Item 4.</B><FONT STYLE="font-size: 3pt">&nbsp;</FONT><B>Purpose
of Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Item 4 is amended to add the following
immediately following the fifth paragraph:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On June 17, 2024, the Issuer and Gilead entered into:
(1) Amendment No. 1 to Common Stock Purchase Agreement (the &ldquo;<U>SPA Amendment</U>&rdquo;) and (2) Amendment No. 1 to Investor Rights
Agreement (the &ldquo;<U>IRA Amendment</U>&rdquo; and, together with the SPA Amendment, the &ldquo;<U>Amendments</U>&rdquo;), which amend
the Common Stock Purchase Agreement (the &ldquo;<U>SPA</U>&rdquo;) and the Investor Rights Agreement (the &ldquo;<U>IRA</U>&rdquo; and
together with the SPA, the &ldquo;<U>Equity Agreements</U>&rdquo;), respectively, entered into between the Issuer and Gilead on October
15, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The SPA Amendment (1) extends the Equity Financing
Deadline (as defined in the SPA) from the date that is nine months after the date of the SPA to the date that is 12 months after the date
of the SPA and (2) extends various deadlines relating to the Issuer&rsquo;s ability to require Gilead to purchase additional shares of
Common Stock from six or nine months, as applicable, after the Issuer receives stockholder approval to six or nine months, as applicable,
following the occurrence of the Issuer meeting the Company Additional Share Purchase Condition (as defined in the SPA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The IRA Amendment extends the requirement that the
Issuer use good faith efforts to complete an Equity Financing (as defined in the IRA) from nine months after October 15, 2023 to 12 months
after October 15, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing descriptions of the Amendments are not
complete and are subject to and qualified in their entirety by reference to the full text of such amendments, which are attached as Exhibits
99.1 and 99.2 hereto and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Securities Purchase Agreement and Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On June 17, 2024, pursuant to the 2024 Purchase Agreement,
the Issuer issued and sold to Gilead, and Gilead purchased from the Issuer, 179,500 shares of Common Stock and a warrant to purchase 179,500
shares of Common Stock at a combined purchase price of $15.46 per share of Common Stock and accompanying Warrant.&nbsp;The Warrant is
exercisable, in whole or in part, immediately at an exercise price of $17.00 per share and expires on June 18, 2029. However, the Warrant
cannot be exercised by Gilead if, after giving effect thereto, Gilead would beneficially own, as determined in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the Issuer&rsquo;s outstanding shares of Common Stock, subject
to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing descriptions of the 2024 Purchase Agreement
and the Warrant are not complete and are subject to and qualified in their entirety by reference to the full text of such amendments,
which are attached as Exhibits 99.3 and 99.4 hereto and incorporated herein by reference</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.9pt">CUSIP No. 0453961080</TD>
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.65pt; text-align: right">Page 4</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><B>Item 5.</B><FONT STYLE="font-size: 3pt">&nbsp;</FONT><B>Interest
in Securities of the Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(a)-(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of shares of Common Stock beneficially owned:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10.1pt; text-indent: -10.1pt"><B>Gilead</B></P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1,268,972 shares</B></P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Percent of class:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10.1pt; text-indent: -10.1pt"><B>Gilead</B></P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="width: 68%; border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>19.99%</B></P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The percentage ownership was calculated based upon
6,345,561 shares of common stock of the Issuer issued and outstanding, which 6,345,561 shares is equal to the sum of (i) 5,531,561 shares
of common stock of the Issuer issued and outstanding as of June 14, 2024, as represented by the Issuer to Gilead in the 2024 Purchase
Agreement, plus (ii) 179,500 shares of common stock issued by the Issuer to Gilead on June 17, 2024 pursuant to the 2024 Purchase Agreement,
plus (iii) 634,500 shares of common stock issued by the Issuer to Armistice Capital LLC on June 17, 2024 pursuant to the Securities Purchase
Agreement, dated June 16, 2024, between the Issuer and Armistice Capital LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of shares as to which such person has:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(i)<FONT STYLE="font-size: 3pt">&nbsp;</FONT>Sole power to vote or to direct
the vote:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 10.1pt; text-indent: -10.1pt"><B>Gilead</B></TD>
    <TD STYLE="border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt"><B>1,268,972 shares</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(ii) Shared power to vote or to direct the vote:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 10.1pt; text-indent: -10.1pt"><B>Gilead</B></TD>
    <TD STYLE="width: 68%; border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt"><B>0 shares</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(iii) Sole power to dispose or to direct the disposition of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 10.1pt; text-indent: -10.1pt"><B>Gilead</B></TD>
    <TD STYLE="border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt"><B>1,268,972 shares</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(iv) Shared power to dispose or to direct the disposition of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 10.1pt; text-indent: -10.1pt"><B>Gilead</B></TD>
    <TD STYLE="width: 68%; border-top: #7F7F7F 1pt solid; border-bottom: #7F7F7F 1pt solid; padding-right: 5.65pt; padding-left: 5.65pt"><B>0 shares</B></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the best knowledge of the Reporting Person, none of the individuals
listed on Schedule I beneficially owns any of the Issuer&rsquo;s Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Reporting Person <FONT STYLE="background-color: white">beneficially
owns the Warrant to purchase 179,500 shares of Common Stock that was acquired from the Issuer on June 17,&nbsp;2024. The Warrant held
by the Reporting Person is subject to a limitation pursuant to which the Reporting Persons may not exercise the Warrant if such exercise
would cause the Reporting Person to beneficially own Common Stock in an amount exceeding the &ldquo;Beneficial Ownership Limitation&rdquo;
(as defined in the Warrant) then in effect. The Beneficial Ownership Limitation is subject to adjustment upon 61 days&rsquo; notice by
the holder of the Warrant to the Issuer and, as of the date of this Amendment No. 1, was 19.99% of the number of shares of Common Stock
outstanding. As a result, none of the 179,500 shares of Common Stock underlying the Warrant are deemed to be beneficially owned by the
Reporting Persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.9pt">CUSIP No. 0453961080</TD>
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.65pt; text-align: right">Page 5</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(c) Except as reported in this Amendment No. 1, neither
the Reporting Person nor, to the best knowledge of the Reporting Person, any of the individuals listed on Schedule I have effected any
transactions in the Common Stock during the past sixty (60) days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(d) Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(e) Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><B>Item 6.</B><FONT STYLE="font-size: 3pt">&nbsp;</FONT><B>Contracts,
Arrangements, Understandings or Relationship with Respect to Securities of the Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Except as disclosed in Items 3 and 4 of this Amendment
No. 1, there are no contracts, arrangements, understandings or relationships (legal or otherwise) to which the Reporting Person is a party
with respect to the securities of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><B>Item 7.</B><FONT STYLE="font-size: 3pt">&nbsp;</FONT><B>Materials
to Be Filed as Exhibits</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Exhibit 99.1<FONT STYLE="font-size: 12pt">&nbsp;</FONT></TD>
    <TD>Amendment No. 1 to Common Stock Purchase Agreement, dated June 17, 2024, between Assembly Biosciences, Inc. and Gilead Sciences, Inc. (incorporated by reference to Exhibit 10.3 of Assembly Biosciences, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2024)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Exhibit 99.2<FONT STYLE="font-size: 12pt">&nbsp;</FONT></TD>
    <TD>Amendment No. 1 to Investor Rights Agreement, dated June 17, 2024, between Assembly Biosciences, Inc. and Gilead Sciences, Inc. (incorporated by reference to Exhibit 10.4 of Assembly Biosciences, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2024)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Exhibit 99.3</TD>
    <TD>Securities Purchase Agreement, dated June 17, 2024, between Assembly Biosciences, Inc. and Gilead Sciences, Inc. (incorporated by reference to Exhibit 10.2 of Assembly Biosciences, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2024)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Exhibit 99.4</TD>
    <TD>Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 of Assembly Biosciences, Inc.&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2024)</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.9pt">CUSIP No. 0453961080</TD>
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.65pt; text-align: right">Page 6</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">After reasonable inquiry and to the best of the undersigned&rsquo;s
knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">Date: June 20, 2024</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P></TD>
    <TD COLSPAN="2">GILEAD SCIENCES, INC. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Andrew D. Dickinson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10.25pt; text-indent: -10pt">&nbsp;</TD>
    <TD>Name: </TD>
    <TD>Andrew D. Dickinson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.9pt">CUSIP No. 0453961080</TD>
    <TD STYLE="padding-right: 5.9pt; padding-left: 5.65pt; text-align: right">Page 7</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Schedule I</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The name and present principal occupation of each of
the executive officers and directors of Gilead Sciences, Inc. are set forth below. Unless otherwise noted, each of these persons have
as their business address c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt"><FONT STYLE="font-size: 9pt"><B>Name</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Title</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Citizenship</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Principal Occupation and, if not employed by Gilead Sciences, Inc., Name, Principal Business and<BR>
Address of Employer</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Daniel P. O&rsquo;Day</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Chief Executive Officer, Chairman and Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Jacqueline K. Barton, Ph.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Professor Emerita, California Institute of Technology</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Jeffrey A. Bluestone, Ph.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">President and Chief Executive Officer, Sonoma Biotherapeutics</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Sandra J. Horning, M.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Retired Chief Medical Officer, Roche Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Kelly A. Kramer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Retired Executive Vice President and Chief Financial Officer, Cisco Systems, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ted W. Love,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">M.D.</P></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Chair of Board of Directors, Biotechnology Innovation Organization</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Harish Manwani</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Singapore</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Senior Operating Partner, Blackstone </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Javier J. Rodriguez</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Mexico</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Chief Executive Officer, DaVita, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Anthony Welters</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Chairman and Chief Executive Officer, CINQ Care</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Andrew D. Dickinson</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Chief Financial Officer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Johanna Mercier</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Chief Commercial Officer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Merdad V. Parsey, M.D., Ph.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Chief Medical Officer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.9pt">Deborah H. Telman</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">Executive Vice President, Corporate Affairs and General Counsel</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.9pt; padding-bottom: 6pt; padding-left: 5.65pt">*</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* The present principal occupation for each of these individuals is officer
of Gilead Sciences, Inc. and officer, trustee and/or director of other affiliated entities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
